Company Profiles

driven by the PitchBook Platform

GeneAssess

GeneAssess
2012 FOUNDED
PRIVATE STATUS
Seed LATEST DEAL TYPE
$500K LATEST DEAL AMOUNT
1 INVESTORS
Description

Developer of advanced diagnostic and genetic tests intended to offer mechanistically-based, percision cancer therapies using FRY signal targeting methodology. The company's advanced diagnostic and genetic tests can be used for assessing cancer risk based on the expression and the DNA sequence of the FRY, enabling physicians to diagnose, treat and improve outcomes for cancer patients.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Laboratory Services (Healthcare)
Other Healthcare Services
Primary Office
  • 120 Albany Street
  • Tower II, Suite 850
  • New Brunswick, NJ 08901
  • United States

+1 (908) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore GeneAssess’s full profile, request a free trial.

GeneAssess Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 29-Jun-2012 $500K 00000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

GeneAssess Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Foundation Venture Capital Group Venture Capital Minority 000 0000 000000 0

GeneAssess Executive Team (2)

Name Title Board
Seat
Contact
Info
Helmut Zarbl Ph.D Founder, Board Member, Founding President and Chairman of Scientific Board

1 Former Executive

You’re viewing 1 of 2 executives. Get the full list »

GeneAssess Board Members (2)

Name Representing Role Since Contact
Info
Helmut Zarbl Ph.D GeneAssess Founder, Board Member, Founding President and Chairman of Scientific Board 000 0000
James Golubieski Foundation Venture Capital Group Board Member 000 0000